The effect of Brazilian Green Propolis extract on inflammation in patients with chronic kidney disease on peritoneal dialysis: A randomised double-blind controlled clinical trial

• Published in: Phytomedicine (Stuttgart) Vol. 114; p. 154731
• Main Authors: Baptista, Beatriz Germer, Fanton, Susane, Ribeiro, Márcia, Cardozo, Ludmila FMF, Regis, Bruna, Alvarenga, Livia, Ribeiro-Alves, Marcelo, Berretta, Andresa A., Shiels, Paul G., Mafra, Denise
• Format: Journal Article
• Language: English
• Published: Germany Elsevier GmbH 01.06.2023
• Subjects: Animals; Biomarkers; Brazil; Carotid Intima-Media Thickness; Chronic kidney disease; Double-Blind Method; Humans; Inflammation - drug therapy; Leukocytes, Mononuclear - metabolism; NF-E2-Related Factor 2 - metabolism; NF-kappa B - metabolism; Oxidative stress; Peritoneal Dialysis; Propolis; Propolis, Inflammation; Renal Insufficiency, Chronic - drug therapy; Tumor Necrosis Factor-alpha; Brazil; CRP; Oxidative stress; MCP-1; RNA; HO-1; mRNA; MDA; Peritoneal dialysis; SC; NF-κB; CIMT; IFN-γ; UFF; Nrf2; cDNA; mg; 24HR; NKF-KDOQI; BMI; ml; IL; EPP-AF; g/kg/day; Chronic kidney disease; TBARS; EDTA; PBMCs; IκBα; VCAM-1; PD; TNF-α; ROS; RJ; Propolis, Inflammation; ELISA; ERK
• ISSN: 0944-7113; 1618-095X
• DOI: 10.1016/j.phymed.2023.154731

•Propolis, a resin produced by bees, is rich in polyphenolic compounds.•Propolis may mitigate inflammation and oxidative stress by reducing pro-inflammatory cytokines.•Propolis supplementation significantly reduced levels of TNF-α expression.•Propolis supplementation showed a tendency to increase the mRNA expression of Nrf2. Chronic kidney disease (CKD) patients on dialysis display a low-grade systemic inflammatory burden. Nutritional interventions designed to activate the cytoprotective nuclear factor erythroid-2-related factor 2 (Nrf2) and inhibit nuclear factor-kB (NF-κB) have been proposed to mitigate this burden. Several bioactive compounds have been investigated to achieve this, including propolis, a resin produced by Apis mellifera bees. Considering the safety and efficacy of propolis, it could be a strategy to benefit these patients. Still, there are no studies using propolis in patients with CKD on peritoneal dialysis (DP), and clinical studies to support this application are lacking. The objective and novelty of the present study are to evaluate the effects of propolis supplementation on inflammatory markers in patients with CKD on PD. A longitudinal, double-blind, placebo-controlled trial with CKD patients on PD. The patients were randomised into two groups: propolis that received four capsules of 100 mg (400 mg/day), containing concentrated and standardised dry EPP-AF® Brazilian green propolis extract) or placebo, four capsules of 100 mg (400 mg/day), of magnesium stearate, silicon dioxide, and microcrystalline cellulose, for two months. Plasma levels of inflammatory cytokines, including tumour necrosis factor (TNF-α) and interleukin-6 (IL-6), were evaluated by ELISA. Quantitative real-time PCR analyses were performed to evaluate the transcriptional expression levels of Nrf2 and NF-κB in peripheral blood mononuclear cells (PBMCs). Plasma malondialdehyde (MDA) levels, a lipid peroxidation marker, was measured as thiobarbituric acid reactive substances (TBARS). Routine biochemical markers, including C-reactive protein (CRP), were analysed using commercial kits. Carotid Intima-Media Thickness (CIMT) was measured with a doppler ultrasonography device. The study was registered on ClinicalTrials.gov under the number NCT04411758. A total of 19 patients completed the study, ten patients in the propolis group (54 ± 1.0 years, five men, 7.2  (5.1) months on PD) and 9 in the placebo group (47.5 ± 15.2 years, three men, 10.8  (24.3) months on PD). The plasma levels of TNF-α reduced significantly (p = 0.02), and expression of Nrf2 showed a trend to increase (p = 0.07) after propolis supplementation. EPP-AF® Green Propolis extract (400 mg/day) supplementation for two months appears as a potential strategy to mitigate inflammation, reducing TNF-α plasma levels in CKD patients on PD. [Display omitted]